Share on StockTwits

Shire PLC (LON:SHP)‘s stock had its “outperform” rating reaffirmed by stock analysts at Cowen and Company in a report issued on Wednesday.

A number of other analysts have also recently weighed in on SHP. Analysts at Bank of America raised their price target on shares of Shire PLC from GBX 3,859 ($65.67) to GBX 4,500 ($76.58) in a research note on Wednesday. They now have a “buy” rating on the stock. Separately, analysts at Shore Capital reiterated a “buy” rating on shares of Shire PLC in a research note on Wednesday. Finally, analysts at Barclays reiterated an “overweight” rating on shares of Shire PLC in a research note on Wednesday. They now have a GBX 3,900 ($66.37) price target on the stock. One analyst has rated the stock with a sell rating, seven have issued a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the company’s stock. Shire PLC presently has a consensus rating of “Buy” and an average price target of GBX 3,096.81 ($52.70).

Shire PLC (LON:SHP) opened at 4489.00 on Wednesday. Shire PLC has a 1-year low of GBX 1989.00 and a 1-year high of GBX 4491.00. The stock has a 50-day moving average of GBX 3526.33 and a 200-day moving average of GBX 3166.. The company’s market cap is £26.229 billion.

Shire plc (LON:SHP) is a specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.